INVESTOR RELATIONS

Successful rights issue strengthens the company’s position

Second quarter 20255 | CEO’s comment


With a strengthened financial position, we can now fully focus on what is central – driving clinical development forward at a rapid pace so that we can achieve our goal: for arfolitixorin to reach the market and help hundreds of thousands of cancer patients achieve better treatment outcomes, says CEO, Petter Segelman Lindqvist.

Read the press release and the report >>
Webcast Q2 2025 >>

Petter Segelman Lindqvist

Petter Segelman Lindqvist, CEO

INVESTORS – latest reports and presentations

New number of shares and votes in Isofol

GOTHENBURG, Sweden, July 31, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes in the company.The information…

SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS

About arfolitixorin

Want to know more about the the drug candidate arfolitxorin?

Last updated 09-16-2025

Scroll to Top